New scan could spot pancreatic cancer relapse months earlier

NCT ID NCT06659705

Recruiting now Diagnosis Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new type of PET scan that uses a tracer called FAPI to see if it can find pancreatic cancer progression or relapse earlier than standard CT or MRI scans. 35 adults with non-spread pancreatic cancer will receive the FAPI-PET scan at several points during their treatment. The goal is to see if this imaging method can detect changes sooner, which could lead to earlier treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 68Ga-FAPI-46 (a radioactive tracer used in PET scans)
What this could lead to: If successful, this imaging method could help doctors spot pancreatic cancer return or spread much earlier than current scans, potentially improving treatment timing.
What could go wrong: This is a small early-phase study (35 people) focused on imaging accuracy, not treatment. The tracer may not prove more useful than existing methods, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC DUCTAL ADENOCARCINOMA (PDAC)

Contacts and locations

Locations

Institut Curie -site Saint-Cloud
RECRUITING

Saint-Cloud, 92210, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.